Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- the role abdominal ultrasound in assessment inflammatory bowel disease
研究概览
简要总结
assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient also including extra intestinal features such as the splanchnic vessels,mesentery and lymph nodes . Doppler u.s can evaluate bowel wall vascularity In activity and remission . peripheral hemogram in relationship to activity inflammatory bowel disease asses anemia ,increase monocyte and decrease mean platelet volume( MPV) . also,the investigator will evaluate the outcome of different lines of treatment traditional and biologic therapy (response to treatment,times of activity and complications)
详细描述
the participants will follow up the patient for 1 year in the first visit
All patients in this study will be subjected to:
-
Detailed history.
-
Careful physical examination
-
laboratory investigation
-
complete blood picture.
-
liver function
-
kidney function
-
Iron profile(serum iron ,serum ferritin
-
ESR (erythrocyte sedimentation rate )
g-CRP (C reactive protein) f-LDH (lactate dehydrogenase) 4. Abdominal us(the colon wall thickness,lymph nodes,mass,other organs) 5. Doppler us (mesenteric vessels) 6. colonoscopy after 1 year of treatment follow up every 3 months by abdominal US and peripheral hemogram and last visit after 1 year colonoscopy and biopsy for assessment response to treatment
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 15 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
patient on traditional therapy
Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)
干预措施: Infliximab (Drug)
patient on infliximab
drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months
干预措施: Infliximab (Drug)
结局指标
主要结局
the role abdominal ultrasound in assessment inflammatory bowel disease
时间窗: 2 year
measure the thickness of the colon by abdominal ultrasound and doppler mesenteric vessels .more than 4ml detect activity doppler mesenteric highly vascularity in activity
次要结局
未报告次要终点
研究者
hyam fathy
clinical professor
Assiut University